Vitiligo drugs market

Q: Which is the major region in the market?

North America is the major region in the market. Read more

Vitiligo Drugs Market, by Drug Class (Calcineurin Inhibitors, Corticosteroids, and Psoralens), by Type (Segmental and Non-segmental), by Route of Administration (Oral and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

Request Free Sample

Jun 2021
CMI2447
195 Pages
Excel & Pdf
Pharmaceutical

Summary

Vitiligo is a skin condition, in which patches of skin lose their color. The total skin area can be affected by vitiligo. This skin disease varies from person to person, it can affect eyes, inside of the mouth, and hair. It is difficult to predict the spread of the patches and by how much. The major symptom for vitiligo is appearance of white spots or patches on skin. There are two major types of vitiligo such as segmental vitiligo and non-segmental vitiligo. Calcineurin Inhibitors, Corticosteroids, and Psoralens are some major drugs indicated by doctors for the treatment of vitiligo disease. Major factors that are expected to fuel growth of the market during the forecast period include increasing drug approvals, investments in research and development of drugs, and strategic expansions by players operating in vitiligo drug market to strengthen their geographical footprint.

Vitiligo Drug Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sectors is one of the sectors is one the sectors, which is majorly impacted by the COVID 19 pandemic. Coronavirus pandemic has negatively impacted the development, production, and supply of medicines and also affected growth of the pharmaceutical businesses of various companies across the globe, as COVID-19 pandemic has led to lockdown in several countries, globally. This lockdown has resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the pharmaceuticals and kits for diagnostic and therapeutic use. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) By directly affecting the production and demand; 2) By creating disruptions in distribution channels; and 3) By its financial impact on firms and financial markets

The global vitiligo drug market is estimated to be valued at US$ 151.9 million in 2020, and is expected to exhibit a CAGR of 12.6% during the forecast period (2020-2027).

Figure 1.: Global Vitiligo Drug Market Share (%) Product Type, 2020-2027

Increasing number of clinical trial and product approvals are expected to drive growth of the global vitiligo drug market.

Major factors assisting the market growth during the forecast period include rising focus on development of drugs to treat vitiligo disease. For instance, in December 2019, Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib.

Furthermore, increasing demand for drugs for efficient treatment of vitiligo is expected to drive growth of the global vitiligo drugs market during the forecast period. For instance, in November 2019, Temprian Therapeutics Inc., a Chicago-based startup company dedicated to developing therapies for autoimmune disease, announced the in-licensure of a pending composition-of-matter patent for a DNA-based drug encoding the modified heat shock protein, HSP70i, from Northwestern University. The company has worked closely with the vitiligo patient community for the development of a safe, non-invasive, market-oriented treatment for vitiligo. The HSP70i-based drug is designed to slowdown autoimmunity, stops the spread of the disease, and trigger repigmentation.

Vitiligo Drug Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 151.9 Mn
Historical Data for:	2017 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	12.9%	2027 Value Projection:	US$ 348.3 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Type: Marketed Drug: Calcineurin Inhibitors, Corticosteroids, Psoralens Pipeline Drug: Ruxolitinib (Phase 3) By Indication Type: Segmental Vitiligo, Non-segmental Vitiligo By Route of Administration: Oral, Topical By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd., Bristol - Myers Squibb, Pfizer Inc., Clinuvel Pharmaceuticals Ltd., Boston Pharmaceuticals, Applied Biology, Inc., Arcutis Biotherapeutics, Inc., Villaris Therapeutics, Arrien Pharmaceuticals LLC, and Temprian Therapeutics Inc.
Growth Drivers:	Product approvals and launch Increasing number of clinical trials
Restraints & Challenges:	Availability of advance technology and alternative therapies for treatment of vitiligo disease

Global Vitiligo Drug Market – Restraints

Availability of advanced technologies for vitiligo treatment is expected to hinder growth of the market. False positive reports are also expected to hamper growth of the market. For instance, in October 2018, STRATA Skin Sciences, a manufacturer of innovative products for treatment of skin conditions, announced the launch of XTRAC S3 308nm Laser at the American Society for Dermatologic Surgery meeting. The XTRAC S3 308nm Laser is used for treating skin disorders such as psoriasis and vitiligo. The XTRAC laser utilizes therapeutic ultra-violet B light to treat affected skin areas without damaging surrounding healthy skin.

Global Vitiligo Drug Market – Regional Analysis

On the basis of region, the global vitiligo drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to be the most lucrative region in the vitiligo drug market during the forecast period. The increasing number of R&D activities and pipeline vitiligo drug candidates are major factors propelling growth of the North America vitiligo drug market. For instance, in June 2019, phase II clinical trial conducted by Tufts Medical Center in Boston found that a topical cream - ruxolitinib, was effective in improving facial vitiligo symptomsMoreover, increasing prevalence of vitiligo in Brazilian population is expected to aid in the market growth in Latin America. For instance, according to the Pigment Cell & Melanoma Journal: 2017, out of 6,048 candidates interviewed, 97 residents reported to have vitiligo. Therefore, there is around 1.15% prevalence of vitiligo in Brazil.

Figure 2.: Global Vitiligo Drug Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Global Vitiligo Drug Market - Competitive Landscape

Key players operating in the global vitiligo drug market market include Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddy’s Laboratories Ltd., Bristol - Myers Squibb, Pfizer Inc., Clinuvel Pharmaceuticals Ltd., Boston Pharmaceuticals, Applied Biology, Inc., Arcutis Biotherapeutics, Inc., Villaris Therapeutics, Arrien Pharmaceuticals LLC, and Temprian Therapeutics Inc.

Table of Content

Table of Contents

*Browse 44 market data tables and 37 figures on "Global Vitiligo Drug Market” - Forecast to 2027”

N/A

- Frequently Asked Questions -

What will be the compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global vitiligo drug market is expected to exhibit a CAGR of market is 12.6% during the forecast period (2020-2027).

What is the estimated market size of the market in 2020?

The market is estimated to be valued at US$ 151.9 million in 2020.

Which are the prominent players operating in the market across the globe?

The prominent players operating in the market include Dermavant Sciences, Inc., Incyte Corporation, Aclaris Therapeutics, Inc., Dr. Reddys Laboratories Ltd., Bristol - Myers Squibb, Pfizer Inc., Clinuvel Pharmaceuticals Ltd., Boston Pharmaceuticals, Applied Biology, Inc., Arcutis Biotherapeutics, Inc., Villaris Therapeutics, Arrien Pharmaceuticals LLC, and Temprian Therapeutics Inc.

What are the growth estimates for the market till 2027?

The market is expected to be valued at US$ 348.3 million in 2027.

Which is the major region in the market?

North America is the major region in the market.

What are the key factors driving growth of the market?

Product approvals and launches and increasing number of clinical trials of drugs to treat vitiligo disease are expected to drive growth of the global vitiligo drug market during the forecast period.